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Abstract 
The prognosis of patients with locally advanced pancreatic cancer can be improved if 
secondary complete (R0) resection is possible. In patients initially staged as unresectable this 
may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We 
report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic 
cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy 
regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of 
FOLFIRINOX. Neoadjuvant chemotherapy resulted in secondary resectability (R0 resection). 
After 2 cycles of nab-paclitaxel plus gemcitabine, the patient already had a complete 
metabolic remission as measured by integrated fludeoxyglucose (
18
F) positron emission 
tomography and computerized tomography. After a follow-up of 18 months the patient is 
alive without progression of disease. We propose to assess the clinical benefit of sequencing 
the combinations nab-paclitaxel plus gemcitabine and FOLFIRINOX as neoadjuvant therapy 
for patients with locally advanced and initially unresectable pancreatic cancer in a controlled 
clinical trial. © 2014 S. Karger AG, Basel 
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Introduction 
Roughly 30–40% of patients with pancreatic ductal adenocarcinoma (PDAC) have local-
ly advanced disease. Their prognosis is not really different from that of patients with 
metastatic PDAC [1]. In about one third of the patients, resectability can be achieved with 
neoadjuvant chemotherapy and/or chemoradiotherapy. If complete (R0) resection is 
possible, patients have a similar overall survival (OS) as those with an initially resectable 
PDAC. These are the results of a meta-analysis of 111 trials with a total of 4,394 patients and 
mainly 5-fluorouracil- or gemcitabine-based neoadjuvant chemoradiotherapy. Initially 
nonresectable patients reached an estimated median OS of 20.5 months (range 9–62 
months) following resection [1]. 
Recently, 2 large phase III trials in patients with metastatic PDAC demonstrated encour-
aging improvements in clinical benefit for 2 combination therapies over single-agent 
gemcitabine [2, 3]. In one trial, the combination of oxaliplatin, 5-fluorouracil, leucovorin and 
irinotecan (FOLFIRINOX) significantly improved median OS to 11.1 months as compared to 
6.8 months for gemcitabine [hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.45–0.73, 
p < 0.001] and median progression-free survival to 6.4 versus 3.3 months (HR 0.47; 95% CI 
0.37–0.59, p < 0.001), respectively. The overall response rate with the combination was 31.6 
as compared to 9.4% with gemcitabine alone. There was 1 (0.6%) reported complete 
response with this combination. The treatment with FOLFIRINOX resulted in significantly 
more adverse events of grade ≥3 in terms of neutropenia (45.7% for FOLFIRINOX vs. 21.0% 
for gemcitabine), febrile neutropenia (5.4 vs. 1.2%), thrombocytopenia (9.1 vs. 3.6%), 
diarrhea (12.7 vs. 1.8%) and peripheral neuropathy (9.0 vs. 0%), while the incidence of 
alanine aminotransferase elevation was decreased (7.3 vs. 20.8%) [2].  
The combination of nab-paclitaxel plus gemcitabine was studied in the pivotal phase III 
trial MPACT. A total of 861 patients with metastatic PDAC received first-line chemotherapy 
either with the combination of nab-paclitaxel at 125 mg/m2 and gemcitabine at 1,000 
mg/m2, both administered on days 1, 8, 15, 29, 36, and 43 of a 56-day cycle with subsequent 
cycles on days 1, 8, and 15 of a 28-day cycle, or with gemcitabine monotherapy at 1,000 
mg/m2 weekly for 7 out of 8 weeks in the first cycle and in subsequent cycles on days 1, 8, 
and 15 of a 28-day cycle. Median OS significantly increased to 8.7 months (95% CI 7.89–
9.69) as compared to 6.6 months (95% CI 6.01–7.20) with gemcitabine alone (HR 0.72; 95% 
CI 0.620–0.825, p < 0.0001) and median progression-free survival was 5.5 versus 3.7 months 
(HR 0.69; 95% CI 0.58–0.82, p < 0.001), respectively. The combination of nab-paclitaxel plus 
gemcitabine resulted in an overall response rate of 23 versus 7% with gemcitabine 
monotherapy (p < 0.001) [3, 4]. There was 1 (0.2%) reported complete response with this 
combination. The most frequently observed adverse events of grade ≥3 were neutropenia 
(38% for nab-paclitaxel and gemcitabine vs. 27% for gemcitabine alone), leukopenia (31 vs. 
16%), fatigue (17 vs. 7%) and neuropathy (17 vs. 1%) [3]. The results of this trial led to the 
approval of the combination of nab-paclitaxel and gemcitabine in the European Union as  
the first-line treatment for patients with metastatic pancreatic adenocarcinoma in January 
2014 [5]. 
Thus, both combinations offer a markedly increased efficacy compared to prior standard 
systemic therapy in the metastatic setting of PDAC. Based on these encouraging data we 
treated a patient with an initially unresectable, locally advanced PDAC with a novel 
neoadjuvant chemotherapy consisting of a sequence of these combination regimens, i.e. nab-
paclitaxel plus gemcitabine followed by FOLFIRINOX.  
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Case Presentation 
In December 2012, a 46-year-old female patient presented to our center with jaundice. 
She was otherwise asymptomatic and in an excellent performance status. She reported no 
comorbidities and neither alcohol nor nicotine abuse nor prior diabetes mellitus. Family 
history concerning malignancies was also negative. Laboratory findings were typical of 
cholestasis with an elevated concentration of total serum bilirubin to 8.4 mg/dl. The level of 
the tumor marker CA 19-9 was increased to 171 U/ml. Abdominal ultrasound revealed a 
dilation of the ductus hepatocholedochus (DHC) but no detectable tumor mass. Endoscopic 
retrograde cholangiopancreatography showed a malignant stenosis of the DHC. A stent was 
placed into the DHC to allow biliary drainage, and as a result total serum bilirubin decreased 
to a normal value within a few days. Endosonography revealed a hypoechoic lesion in the 
pancreatic head between DHC and the portal vein in the vicinity of the celiac trunk as well as 
suspicious locoregional lymph nodes. There were, however, no tumor cells in the bioptic 
material gained repeatedly during this session. Integrated fludeoxyglucose (18F) positron 
emission tomography (PET)-computed tomography (CT) found a PET-avid tumor in the 
pancreatic head largely adjacent to the celiac trunk and a PET-avid regional lymph node 
metastasis (fig. 1). There were no signs of peritoneal carcinomatosis or distant metastasis. 
An exploratory laparotomy confirmed the diagnosis of PDAC by intraoperatively frozen 
sections and the suspected unresectability which was due to an encasement of the celiac 
trunk (>180°) by the pancreatic tumor. Histology detected a moderately differentiated 
pancreatic adenocarcinoma surrounded by stromal desmoplasia. Thus, the locally advanced 
PDAC could be classified as pT4 Nx cM0 G2. During surgery, the patient received a biliodiges-
tive anastomosis using Roux-en-Y anastomosis and a central venous port system. 
Three weeks after surgery, intensified neoadjuvant chemotherapy was started with the 
objective to achieve secondary resectability. The patient was given 2 cycles of a combination 
of nab-paclitaxel plus gemcitabine. Nab-paclitaxel was given at a dose of 125 mg/m2 on days 
1, 8 and 15, gemcitabine at a dose of 1,000 mg/m2 on days 1, 8 and 15, both repeated on day 
29. Chemotherapy was tolerated well. The patient developed grade 2 neutropenia and grade 
1 fatigue. Treatment resulted in a complete metabolic remission. The follow-up PET-CT 
showed no more PET-avid lesions (fig. 2).  
Chemotherapy was continued with 4 cycles of FOLFIRINOX. Oxaliplatin was adminis-
tered at a dose of 85 mg/m2 on day 1, leucovorin at a dose of 400 mg/m2 on day 1, and 
irinotecan at a dose of 180 mg/m2 on day 1 followed by continuous infusion of 5-fluorouracil 
over 46 h at a dose of 2,400 mg/m2. Cycles were repeated every 2 weeks. Side effects were 
grade 1 neutropenia, grade 2 fatigue, grade 1 diarrhea and grade 1 peripheral neuropathy. 
The follow-up PET-CT confirmed the complete metabolic remission; yet, it also showed 
a persistent tumor abutment of the celiac trunk, formally still unresectable according to 
NCCN guidelines (fig. 3). 
In June 2013, a second laparotomy was performed. No vital tumor cells were found in 
the biopsies taken intraoperatively (frozen sections) of the tissue surrounding the celiac 
trunk and the DHC stump. Thus, a pylorus-preserving resection of the pancreatic head, 
regional lymphadenectomy, pancreaticojejunostomy and antecolic duodenojejunostomy 
were performed. 
Surgery resulted in resection-free margins (R0 resection). The pancreatic tumor was 2.2 
cm in diameter. Of the 33 lymph nodes that were resected, 2 showed micrometastases. Thus, 
the postoperative pathology result was ypT3 (2.2 cm) ypN1 (2/33; 1 mm) L0 V0 Pn1, local 
R0. Less than 10% vital tumor cells were found in the resection specimen, corresponding to 
Evans Regression Score grade III [6].  
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Subsequently, the patient was given 2 cycles of adjuvant chemotherapy with gemcita-
bine from July to September 2013. The patient was alive 18 months after the primary 
diagnosis at the last follow-up visit in April 2014. She showed a good performance status and 
had no signs of recurrent disease. 
Discussion 
Our case shows that secondary R0 resection can be achieved with neoadjuvant chemo-
therapy utilizing modern combination regimens. This is relevant as patients with an initially 
unresectable locally advanced PDAC have a similar prognosis to patients with a primarily 
resectable pancreatic cancer if R0 resection can be achieved [1]. However, it needs to be 
stressed that the concept of neoadjuvant therapy in locally advanced unresectable PDAC and 
its actual clinical benefits still have to be proven, since evidence from prospective, random-
ized trials is still lacking.  
After a follow-up of 18 months, our patient was still progression free. The neoadjuvant 
chemotherapy we chose was actually a sequence of the 2 most active regimens for metastat-
ic PDAC known today. The patient tolerated this intensified chemotherapy well. However, 
she already showed complete metabolic remission after 2 cycles of nab-paclitaxel plus 
gemcitabine. In the pivotal trial in metastatic PDAC, patients with a biochemical response 
after nab-paclitaxel plus gemcitabine had a better outcome than patients without a PET-
response [7]. There are also data suggesting that a metabolic PET response may be of 
predictive value for patients with locally advanced pancreatic carcinoma treated with 
definitive concurrent chemoradiotherapy [8]. 
It is unclear to what extent the sequential treatment with FOLFIRINOX improved clinical 
outcome or whether neoadjuvant chemotherapy with the combination of nab-paclitaxel plus 
gemcitabine alone would have sufficed. This will be the objective of the randomized phase II 
trial NEOLAP that will start in September 2014. In this trial, patients with locally advanced, 
initially unresectable or borderline-resectable PDAC will either receive neoadjuvant 
chemotherapy with 4 cycles of nab-paclitaxel plus gemcitabine or 2 cycles of nab-paclitaxel 
plus gemcitabine followed by 4 cycles of FOLFIRINOX. The R0 resection rate will be the 
primary endpoint. 
The primary tumor of our patient showed extensive stromal desmoplasia which is a 
typical feature of PDAC. The concept of stromal depletion has been identified as a promising 
therapeutic route in the treatment of pancreatic cancer [9]. Preclinical data show that the 
treatment with nab-paclitaxel results in depleting desmoplastic stroma and reducing stromal 
density of pancreatic tumor tissue [10, 11]. The effect of stromal depletion was highest with 
the combination of nab-paclitaxel and gemcitabine [11]. There is also clinical evidence from 
a neoadjuvant trial in 16 patients with resectable pancreatic cancer treated with 2 cycles of 
nab-paclitaxel plus gemcitabine before surgical resection. Of the 12 patients who completed 
treatment, 7 were R0 resected with major pathological regressions. A significant decrement 
in tumor stiffness was measured by endoscopic ultrasound elastography. Histology showed 
a change in the architecture of the tumor stroma as indicated by markedly disorganized 
collagen and a very low density of cancer-associated fibroblasts, which was not observed in 
the untreated or conventionally treated control groups. A preclinical, co-clinical study in a 
mouse model showed that these effects were specific of nab-paclitaxel and not of gemcita-
bine [12]. The precise mechanism of stroma depletion by nab-paclitaxel is currently not 
known and has to be defined in further preclinical and clinical studies. Among the multitude 
of stromal components, the matricellular glycoprotein secreted protein acidic and rich in 
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cysteine (SPARC) has attracted particular interest. However, despite encouraging data from 
previous phase I/II trials, extensive SPARC analysis within a phase III trial (MPACT trial) 
failed to demonstrate any prognostic or predictive role of stromal and/or tumor SPARC 
expression in the metastastic setting [13]. 
In conclusion, chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFI-
RINOX was an effective and well-tolerated neoadjuvant treatment in a patient with initially 
irrresectable, locally advanced PDAC which resulted in secondary resectability (R0 
resection). Not only the clinical benefit of sequencing both combination regimens as 
neoadjuvant therapy for patients with locally advanced PDAC, but also the general concept 
of neoadjuvant treatment in locally advanced pancreatic cancer needs to be assessed in 
future prospective clinical trials. 
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Fig. 1. January 2013. Tumor lesions in the primary tumor and lymph nodes prior to chemotherapy.  
a Fused PET-CT and PET of the primary tumor. b Fused PET-CT and PET of the regional lymph node 
metastases. 
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Fig. 2. March 2013. Tumor lesions in the primary tumor and lymph nodes after 2 cycles of nab-paclitaxel 
plus gemcitabine. a Fused PET-CT and PET of the primary tumor. b Fused PET-CT and PET of the regional 
lymph node metastases. 
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Fig. 3. June 2013. Tumor lesions in the primary tumor and lymph nodes after 4 cycles of FOLFIRINOX.  
a Fused PET-CT and PET of the primary tumor. b Fused PET-CT and PET of the regional lymph node 
metastases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
